Physician profile
Ravi Kumar
NPI 1679270177
$3,791.36
in general payments reported to CMS, 2019-2025
20 companies · $1,177 in 2025
The $1,177 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $937 · 2024: $1,678 · 2025: $1,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,791.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $729.78 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $729.71 | 2023-2025 | Relistor, Trulance |
| Forte Bio-Pharma LLC | $620.52 | 2023-2025 | Prolate, Nalocet, Tanlor |
| Astrazeneca Pharmaceuticals LP | $447.28 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $232.43 | 2023-2025 | |
| Lilly USA, LLC | $139.10 | 2023-2025 | Mounjaro, Reyvow, Emgality |
| Kyowa Kirin, INC. | $138.10 | 2023 | Crysvita |
| Novo Nordisk INC | $136.44 | 2023-2025 | Ozempic, Rybelsus |
| Curonix LLC | $122.59 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Bayer Healthcare Pharmaceuticals INC. | $117.82 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $102.50 | 2024 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $90.49 | 2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alnylam Pharmaceuticals INC. | $57.85 | 2023 | Givlaari |
| Spr Therapeutics, INC | $21.27 | 2024 | Sprint Pns System |
| Corcept Therapeutics | $19.38 | 2025 | Korlym |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $18.75 | 2025 | Yupelri |
| Impel Pharmaceuticals LLC | $18.73 | 2025 | Trudhesa |
| Biotronik Nro, INC. | $17.20 | 2024 | Prospera |
| Dexcom, INC. | $17.19 | 2025 | Dexcom G6 Transmitter |
| Scilex Pharmaceuticals INC. | $14.23 | 2023 | Ztlido |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.